Standout Papers

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable he... 2021 2026 2022 2024817
  1. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma (2021)
    Ann‐Lii Cheng, Shukui Qin et al. Journal of Hepatology

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 63 standout
Sub-graph 1 of 22

Citing Papers

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
2024 Standout
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
3 intermediate papers

Works of Alan Nicholas being referenced

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
2021 Standout
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).
2018

Author Peers

Author Last Decade Papers Cites
Alan Nicholas 660 180 412 708 23 1.4k
Leonid Dubrovsky 812 128 268 831 29 1.5k
John A. Conti 1075 118 296 659 24 1.5k
Jessica Spahn 484 135 252 421 25 1.1k
Florian Castet 492 313 356 448 18 1.3k
Laia Bassaganyas 403 312 300 409 21 1.1k
Giovanni Benedetti 1043 149 356 439 20 1.4k
Domenico Magazzù 882 554 207 111 18 1.3k
Stella Y. Tsai 458 316 363 314 24 1.3k
Robert Königsberg 660 354 162 347 31 1.4k
Henry Xiong 758 217 297 155 20 1.1k

All Works

Loading papers...

Rankless by CCL
2026